Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Deverra Therapeutics
Deverra Therapeutics develops allogeneic cellular immunotherapies for patients with hematologic malignances and other critical diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
LIfT BioSciences
LIfT Biosciences develops cancer-killing neutrophils for immuno-oncology cell therapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing T cell engagers to treat cancer and other diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Tmunity Therapeutics
Tmunity Therapeutics develops novel products to unleash the immunological potential of T cells for treating various diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds14
Number of Funding Rounds
Money Raised
Their latest funding was raised on 19.03.2024. Their latest investor Boxer Capital. Their latest round Post-IPO Equity
Co-Investors
Investors10
Number of lead investors
Number of investors
Boxer Capital
Boxer Capital supports biotech public companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Adage Capital Management
Adage Capital Management is a Boston-based capital management firm that focuses on managing S&P 500 assets for endowments and foundations.
Sector
Subsector
Location
count Of Investments
count Of Exists
Deep Track Capital
Deep Track Capital is a Greenwich-based investment firm focused on life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Acquisitions1
Verio Therapeutics acquired by Fate Therapeutics
acquirer
date
type
Verio Therapeutics
Verio Therapeutics develops drugs activating endogenous stem cells in biotechnology.
Sector
Subsector
Location
People
Founders9
Randall Moon
Dr. Moon studies the Wnt signal transduction pathways with an emphasis on their normal roles in vertebrates, their mechanisms of action, their linkage to various disease processes, and the development of therapeutics targeting these pathways. His laboratory employs a wide range of approaches, including high throughput screening for small molecules, advanced mass spectrometry methods, diverse animal model systems and cell biological and biochemical approaches. Dr. Moon is an investigator of the Howard Hughes Medical Institute, and a professor of pharmacology at the University of Washington School of Medicine. He is also the William and Marilyn Connor Chair, and founding director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington. Dr. Moon received his B.A. degree in biology at New College, Sarasota, FL, and his Ph.D. in zoology at the University of Washington. After completing his postdoctoral work in molecular biology at the California Institute of Technology, he joined the faculty of the University of Washington, where he has been the recipient of a Syntex Scholar in Cardiovascular Research, a Career Development Award from the NIH, a recipient of a L.L. Temple Award from the Alzheimer’s Association, and a fellow of the American Association for the Advancement of Science. Additionally, Dr. Moon was elected to the Washington State Academy of Sciences.
current job
organization founded
Randall Moon
Leonard Zon
Founder at CAMP4 Therapeutics, Amagma Therapeutics and Scholar Rock.
current job
organization founded
Leonard Zon
David Scadden
David Scadden, M.D., Gerald and Darlene Jordan Professor of Medicine at Harvard University; Co-Director, Harvard Stem Cell Institute; Chair; Department of Stem Cell and Regenerative Biology, Harvard University; Director, Center for Regenerative Medicine, Massachusetts General Hospital David Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He and Professor Douglas Melton founded and jointly direct the Harvard Stem Cell Institute that is the largest institute dedicated to bringing stem cell biology to medical care in the world. With Professor Melton, Professor Scadden founded and chairs the Department of Stem Cell and Regenerative Biology Department at Harvard University, the first department to span faculties in Harvard’s history. He is a hematologist/oncologist and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and previously chaired the Hematologic Malignancies program in the MGH Cancer Center. He is an expert on the medical applications of stem cell biology with a particular emphasis on their use in the settings of cancer and AIDS. He has published over 300 scientific papers and book chapters and his laboratory has made fundamental contributions in how the stem cell niche regulates stem cell function and in normal and disease-corrupted hematopoiesis. He is the recipient of numerous honors including membership in the National Academy of Medicine, the American Academy of Arts and Sciences and awards from the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Welcome Fund and the Leukemia and Lymphoma Society. He is the recipient of multiple honorary degrees. In 2016, he received the E. Donnall Thomas Prize from the American Society of Hematology. He has served or serves on the Board of Scientific Counselors for the National Cancer Institute, the Board of External Experts for the National Heart, Lung and Blood Institute, Board of Directors of the International Society for Stem Cell Research (ISSCR) and is an Associate Member of the Broad Institute of Harvard and MIT. He serves on multiple editorial boards and scientific advisory boards and is a scientific founder of Fate Therapeutics and Magenta Therapeutics, private biotechnology companies.
current job
organization founded
David Scadden
Sheng Ding
Dr. Ding has been a pioneer in the field of developing and applying innovative chemical approaches to stem cell biology and regeneration, with a focus on discovering and characterizing novel small molecules that can control various cell fate/function, including stem cell maintenance, activation, differentiation and reprogramming in various developmental stages and tissues. Dr. Ding has published over 70 research articles, reviews and book chapters, and made several seminal contributions to the stem cell field. Dr. Ding is currently Senior Investigator and Professor at Gladstone Institute of Cardiovascular Disease, and Department of Pharmaceutical Chemistry, University of California San Francisco. He obtained his B.S. in chemistry with honors from Caltech in 1999, and a Ph.D. in chemistry from Scripps in 2003.
current job
organization founded
Sheng Ding
Employee Profiles51
William Accomando
Senior scientist, bioanalytical development
Ramzey Abujarour
Director, reprogramming and cellular engineering
John Goulding
Senior scientist - cell therapy drug development
Jessica Francis
Executive director, human resources and operations
Activity
Recent News8
The graph reveals the ratio (%) of positive news articles in a chosen time range